Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
RESEARCH TOOLSreports
Holding XFOR?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2020
|% Change Since: -13.56%
|Next Earnings Date:Nov 07, 2019
Earnings Call Sentiment|Positive
The earnings call highlighted positive clinical trial results and strategic advancements for X4 Pharmaceuticals, particularly with mavorixafor's potential in chronic neutropenia and the successful launch of XOLREMDI. However, some concerns were noted regarding flat sales and early study discontinuations.Company Guidance
During the Q3 2024 earnings call, X4 Pharmaceuticals provided comprehensive guidance on their operational and clinical progress, emphasizing the successful completion of their Phase II study of mavorixafor in chronic neutropenia (CN). The company highlighted the drug's potential as both a monotherapy and in combination with G-CSF, noting that mavorixafor consistently increased absolute neutrophil count (ANC) to clinically meaningful levels, even allowing for a 70% reduction in G-CSF doses in some cases. This Phase II study enrolled 23 participants and demonstrated that mavorixafor was generally well-tolerated. On the commercial front, X4 has engaged with 3,400 immunologists and hematologists to boost awareness of their FDA-approved product XOLREMDI for WHIM syndrome, reporting that 75% of likely prescribers are now knowledgeable about the condition. Financially, X4 ended the quarter with $136 million in cash, projecting a runway into late 2025, excluding anticipated revenue growth from XOLREMDI. The call underscored X4's strategic focus on leveraging existing infrastructure to support potential mavorixafor applications in broader CN indications, with ongoing Phase III trials targeting global patient enrollment across 20-25 countries.Positive Phase II Study Results for Mavorixafor in Chronic Neutropenia
The Phase II study showed mavorixafor increased mean absolute neutrophil count (ANC) to normal levels as monotherapy and in combination with G-CSF, with 75% of participants reducing their G-CSF dose.
U.S. FDA Approval and Launch of XOLREMDI
X4 Pharmaceuticals received U.S. FDA approval for XOLREMDI (mavorixafor) for WHIM syndrome, and successfully engaged 3,400 targeted immunologists and hematologists.
Strong Financial Position
X4 Pharmaceuticals ended Q3 2024 with cash and equivalents of $136 million, providing a financial runway into late 2025.
Significant G-CSF Reduction Achieved
In the combination group, G-CSF was reduced by 52% on average at month 3 and 70% at month 6.
High Physician Engagement
75% of surveyed healthcare providers reported they would consider prescribing XOLREMDI for WHIM patients.
---
XFOR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XFOR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.59 | $0.28 | -52.54% |
| Aug 08, 2024 | $0.63 | $0.65 | +3.17% |
| May 07, 2024 | $1.20 | $1.09 | -9.17% |
| Mar 21, 2024 | $1.02 | $1.31 | +28.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does X4 Pharmaceuticals Inc (XFOR) report earnings?
X4 Pharmaceuticals Inc (XFOR) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is X4 Pharmaceuticals Inc (XFOR) earnings time?
X4 Pharmaceuticals Inc (XFOR) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XFOR EPS forecast?
XFOR EPS forecast for the fiscal quarter 2024 (Q4) is -0.17.
---